WILMINGTON, Mass., Nov. 3, 2014 /PRNewswire/ -- Implant
Sciences Corporation (OTCQB: IMSC), a high technology supplier of
systems and sensors for homeland security and defense markets,
announced today it will exhibit at booth C9 at Airport Council
International's ACI Europe & ACI Asia-Pacific Airport Exchange
2014. ACI Airport Exchange is an important event in the air
transport industry, with an expected attendance of more than 2,500
aviation business executives from Europe, Asia
Pacific and around the world.
Implant Sciences, whose systems are the most widely deployed
non-radioactive IMS ETDs in the world, will exhibit its explosives
trace detectors (ETD) including its handheld QS-H150 and its
desktop QS-B220. The QS-B220 is the first and to date only system
in the world to have passed new Common Evaluation Process (CEP)
standards for ETD security equipment performance defined by
44 member nation European Civil Aviation Conference
(ECAC).
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing
advanced detection capabilities to counter and eliminate the
ever-evolving threats from explosives and drugs. The Company's team
of dedicated trace detection experts has developed proprietary
technologies used in its commercial products, thousands of which
have been sold across more than 50 countries worldwide. Implant
Sciences is only the third manufacturer, and the sole
American-owned company, to currently have an ETD system named as a
Qualified Product by the US Transportation Security Administration.
The Company's ETDs have received approvals and certifications from
several international regulatory agencies including the TSA in the
U.S., ECAC in Europe, STAC in
France, the German Ministry of the
Interior, and the Ministry of Public Safety in China. It also received a GSN 2013 Homeland
Security Award for "Best Explosives Detection Solution." All
Implant Sciences products are recognized as Qualified
Anti-Terrorism Technologies by the Department of Homeland Security.
For further details on the Company and its products, please visit
the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking
statements," as that term is defined in the Private Securities
Litigation Reform Act of 1995. Such statements are based on
management's current expectations and are subject to risks and
uncertainties that could cause the Company's actual results to
differ materially from the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the risks that
we will be required to repay all of our indebtedness to our secured
lenders by March 31, 2015; if we are
unable to satisfy our obligations and to raise additional capital
to fund operations, our secured lenders may seize our assets and
our business may fail; we continue to incur substantial operating
losses and may never be profitable; our independent registered
public accounting firm has expressed substantial doubt as to our
ability to continue as a going concern; there is no guaranty that
the Transportation Security Administration (TSA) or any other U.S.
or foreign government and law enforcement agencies or commercial
consumers will purchase any of our explosives detection products or
that any new products we may develop will be accepted by the TSA or
by such other governments, agencies or consumers; economic,
political and other risks associated with international sales and
operations could adversely affect our sales; liability claims
related to our products or our handling of hazardous materials
could damage our reputation and have a material adverse effect on
our financial results; our business is subject to intense
competition; our markets are subject to rapid technology change and
our success will depend on our ability to develop and introduce new
products; we may not be able to retain our management and key
employees or identify, hire and retain additional personnel as
needed; we may not be able to enforce our patent and other
intellectual property rights or operate without infringing on the
proprietary rights of others; and other risks and uncertainties
described in our filings with the Securities and Exchange
Commission, including our most recent Forms 10-K, 10-Q and 8-K.
Such statements are based on management's current expectations and
assumptions which could differ materially from the forward-looking
statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700
or
Investor Contact:
Laurel Moody
646-810-0608
SOURCE Implant Sciences Corporation